315 related articles for article (PubMed ID: 12399758)
1. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
3. Interventions for mycosis fungoides.
Valipour A; Jäger M; Wu P; Schmitt J; Bunch C; Weberschock T
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD008946. PubMed ID: 32632956
[TBL] [Abstract][Full Text] [Related]
4. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
5. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
Papadavid E; Antoniou C; Nikolaou V; Siakantaris M; Vassilakopoulos TP; Stratigos A; Stavrianeas N; Katsambas A
Am J Clin Dermatol; 2008; 9(3):169-73. PubMed ID: 18429646
[TBL] [Abstract][Full Text] [Related]
7. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
8. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
10. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Scarisbrick JJ; Morris S; Azurdia R; Illidge T; Parry E; Graham-Brown R; Cowan R; Gallop-Evans E; Wachsmuth R; Eagle M; Wierzbicki AS; Soran H; Whittaker S; Wain EM
Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.
Straus DJ; Duvic M; Kuzel T; Horwitz S; Demierre MF; Myskowski P; Steckel S
Cancer; 2007 May; 109(9):1799-803. PubMed ID: 17366595
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
Breneman D; Duvic M; Kuzel T; Yocum R; Truglia J; Stevens VJ
Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
[TBL] [Abstract][Full Text] [Related]
14. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
[TBL] [Abstract][Full Text] [Related]
15. Treatment of cutaneous T cell lymphoma: current status and future directions.
Apisarnthanarax N; Talpur R; Duvic M
Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
[TBL] [Abstract][Full Text] [Related]
16. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
17. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Väkevä L; Ranki A; Hahtola S
Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
Singh F; Lebwohl MG
J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
[TBL] [Abstract][Full Text] [Related]
19. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
Rupoli S; Canafoglia L; Goteri G; Leoni P; Brandozzi G; Federici I; Micucci G; Giantomassi F; Mozzicafreddo G; Alterini R; Filosa G; Ricotti G; Simonacci M; Scortechini AR; Zizzi A; Pimpinelli N
Eur J Dermatol; 2016; 26(1):13-20. PubMed ID: 26678311
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.
Cabello I; Servitje O; Corbella X; Bardés I; Pintó X
Clin Exp Dermatol; 2017 Apr; 42(3):276-281. PubMed ID: 28233333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
